Research on the value of montelukast sodium as adjuvant treatment for pediatric bronchiolitis
孟鲁司特钠辅助治疗小儿毛细支气管炎的价值研究

摘要

目的 分析孟鲁司特钠辅助治疗小儿毛细支气管炎的价值。方法 挑选吉林市人民医院门诊两年期间收治的小儿毛细支气管炎患儿（样本纳入时间：2022年10月~2024年10月；样本纳入例数：86例）当作研究对象，以随机分组方法为分组原则，分为对照组（划分到该组的患儿进行布地奈德，n=43）与试验组（划分到该组的患儿进行孟鲁司特钠治疗，n=43）。对比两组的治疗效果及炎症指标。结果 在临床疗效上，试验组高于对照组（P＜0.05）。在白细胞计数与C反应蛋白上，试验组低于对照组（P＜0.05）。结论 孟鲁司特钠辅助治疗小儿毛细支气管炎的效果确切，有助于减轻肺部炎症反应，临床可进一步推广应用。

Abstract

Objective To analyze the value of Montelukast Sodium as an adjuvant therapy for pediatric bronchiolitis.
Methods Children with bronchiolitis admitted to the outpatient department of Jilin People's Hospital during a two-year period (sample inclusion time: October 2022~October 2024; sample inclusion number: 86 cases) were selected as the research subjects. Random grouping was used as the grouping principle, and they were divided into a control group (children assigned to this group received budesonide, n=43) and an experimental group (children assigned to this group received montelukast sodium treatment, n=43). Compare the therapeutic effects and inflammatory indicators between the two groups.
Results In terms of clinical efficacy, the experimental group was higher than the control group (P<0.05). In terms of white blood cell count and C-reactive protein, the experimental group was lower than the control group (P<0.05).
Conclusion   Montelukast sodium has a definite effect as an adjuvant therapy for pediatric bronchiolitis, helping to reduce pulmonary inflammatory reactions, and can be further promoted and applied in clinical practice.